Feasibility Trial of CBT for Depersonalisation in Psychosis

Status Completed

Clinical Trial Summary

This is a feasibility trial designed to test the feasibility and acceptability of a brief form (six sessions) of Cognitive Behavioural Therapy (CBT) for Depersonalisation/Derealisation (DP/DR) in those individuals who also have a diagnosis of a psychotic disorder. Participants will be randomised to receive either six sessions of CBT targeting DP/DR symptoms or to a treatment as usual control condition.

Clinical Trial Description

Depersonalisation/derealisation (DP/DR) are distressing symptoms of having a sense of detachment and unreality about oneself (DP) or the external world (DR). Cognitive Behavioural Therapy (CBT) has been found to be beneficial in treating patients with chronic DP/DR. CBT for DP/DR includes educating patients about these experiences so they have a better understanding and less fear; teaching ways of coping to help them manage the symptoms better; helping reduce the impact on their day to day functioning; and working together to find less distressing ways of interpreting these experiences. Recent research has highlighted that DP/DR symptoms are common in people diagnosed with psychotic disorders, and when present are linked with more severe psychotic symptoms. However, there has been no previous study to ascertain if CBT to target DP/DR in psychosis would be effective. This study therefore aims to establish the feasibility of a brief CBT intervention for DP/DR in people diagnosed with a psychotic disorder. It is hoped that the CBT will reduce the distress associated with DP/DR experiences, with a possibility of reducing psychotic phenomena in addition. The investigators will seek to recruit adults aged 18-70 with a current psychotic symptoms as well as meeting threshold for DP/DR disorder. Participants will be randomly assigned to receive six sessions of CBT or to a treatment as usual control. Outcomes will be assessed at baseline and follow-up interview at 10 weeks. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02427542
Study type	Interventional
Source	King's College London
Contact
Status	Completed
Phase	Phase 1
Start date	March 2015
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321602` - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder	Phase 1
Terminated	`NCT03230097` - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year	Phase 2
Completed	`NCT03497663` - VIA Family - Family Based Early Intervention Versus Treatment as Usual	N/A
Active, not recruiting	`NCT05726617` - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders	N/A
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Recruiting	`NCT02874573` - Tocilizumab in Schizophrenia	Phase 1
Terminated	`NCT02584114` - Brain Effects of Memory Training in Early Psychosis	N/A
Completed	`NCT02906553` - The Role of Nitric Oxide in Cognition in Schizophrenia	N/A
Withdrawn	`NCT02213887` - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications	Phase 4
Completed	`NCT01981356` - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis	Phase 0
Terminated	`NCT02841956` - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement	N/A
Recruiting	`NCT02009969` - Serial Comparisons of Abdominal and Neurological MRI Scans	N/A
Recruiting	`NCT02848469` - Irish Omega-3 Study	Phase 2
Completed	`NCT02648321` - Motivational Intervention for Physical Activity in Psychosis	N/A
Enrolling by invitation	`NCT00762866` - Psychiatric Genotype/Phenotype Project Repository
Completed	`NCT00484302` - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis	N/A
Completed	`NCT00130923` - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder	Phase 4
Completed	`NCT00844922` - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)	Phase 2
Completed	`NCT00455234` - Rapid Tranquillization Trial: TREC-India II	Phase 3
Completed	`NCT00130676` - A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.